PetCaseFinder

Peer-reviewed veterinary case report

Male cat with sudden mammary gland swelling from fibroadenomatous

By Saray Lorna Mayayo et al.·Published in JFMS open reports·2018·View original on Semantic Scholar

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Mammary fibroadenomatous hyperplasia in a male cat

Species:
cat

Plain-English summary

A 2-year-old male European Shorthair cat was brought to the vet with swollen mammary glands that had developed over the past 10 days. After running tests, the vet diagnosed him with mammary fibroadenomatous hyperplasia (MFH), a benign condition usually seen in female cats, likely caused by exposure to hormone-like substances. The treatment involved giving the cat a medication called aglepristone, which blocks progesterone, and within six days, the swelling started to decrease. By four weeks, the cat's condition had completely improved, and the mammary glands returned to normal size.

People also search for: male cat swollen mammary glands · cat fibroadenomatous hyperplasia treatment · aglepristone for cats

Abstract

Case summary Mammary fibroadenomatous hyperplasia (MFH) is a benign pathology characterised by extensive proliferation of the ductal epithelium and mammary stroma. It typically occurs in young female cats, and seems to result from hypersensitivity to progesterone. A 2-year-old entire male European Shorthair cat presented to the veterinary clinic with enlargement of several mammary glands, which had developed within the previous 10 days. There was no prior administration of progestin in the cat’s medical history. Diagnostic tests were performed to assess the basal progesterone concentration and the concentration after stimulation with gonadotropin-releasing hormone, which ruled out the presence of functional ovarian tissue. Histological examination of the testes excluded hormone-secreting testicular tumours. Histological examination of the mammary gland confirmed the diagnosis of MFH. Treatment was started with aglepristone, a selective competitor for progesterone receptors, administered subcutaneously at 15 mg/kg at days 1, 2, 8 and 15. A reduction in the size of the mammary glands was evident 6 days after the first administration, with complete remission observed after 4 weeks. Relevance and novel information To the best of our knowledge, this is the first full report of MFH in a male cat. Although the origin of the progestins responsible for MFH in this case could not be confirmed, in the light of the diagnostic tests performed and the results obtained, accidental contact with hormone-like substances seems to be the only plausible explanation for the cat’s clinical signs. Inhibitor therapy was successful.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on Semantic Scholar: https://www.semanticscholar.org/paper/29568542